Novobliss Research: An Independent Cro Carrying-Out High Performance Global Standard Clinical Research & Clinical Activities

Maheshvari Patel

Founder

Maheshvari Patel

Founder

One of the world's foremost economically advantageous locations for clinical trials now is India. The primary driving force has been the WTO's altered intellectual property laws, and the key ideological basis for the expansion of India's clinical trial business is profit maximization over any kind of altruistic goal. Additionally, due to stringent regulatory standards, clinical trials for FMCG industry have increased.

These products are released based on scientifically evidence-based claim substantiation safety efficacy studies. A distinctive CRO, NOVOBLISS Research provides clinical trial support for some of the major FMCG products that are used on a daily basis with the goal of providing high-quality, scientifically supported data.

Inception Objective
Located in Ahmedabad and operating out of an 8000 square foot facility, NOVOBLISS Research offers science-based, global product development planning and strategy by recognizing the direction to the industry and applicable regulatory requirements, specifying the optimum solutions and regulatory strategy for a successful global market entry, and taking into account potential distinct regulatory obligations contingent on focused local markets.

“We started with a vision to be one of the cost-effective, scientifically data driven, qualitative CRO globally. Having a dedicated, efficient, experienced & passionate team, we are ‘Committed to advancing innovation & science for Healthy life’. We back our clinical evaluations with AI tools, Biomarkers, Microbiomes, and Accurate

Bioinstrumentation for skin, hair, ayurvedic, herbal, personal care, food, nutraceuticals, and pharmaceuticals market segments”, shares Maheshvari Patel, Founder.

NOVOBLISS offers a series of services while focusing on result-oriented qualitative training by experts, validating the test methods & procedures, validation of bio-instrument operators, using electronic data capture tools, 100 percent quality control of clinical data, results, quality assurance, and research publication in high-impact journals. “For overall project management, we have a team of Project Directors, Leaders, Managers, Clinical Research Coordinators, Clinical Research Associates, Quality Assurance Auditors, QC Coordinators, Biostatisticians & Programmers, Pharmacovigilance, and PAN India site availability. We also have tieups with well known universities with whom we collaborate for Pre- Clinical studies, Academic clinical studies placements to nurture the talent”, speaks Nayan Patel, Co-Founder.

Government regulatory organizations, including AYUSH, FSSAI, and self-regulatory group ASCI have enhanced regulations for labeling standards for herbal and food goods. Understanding the requirements for both domestic and international clinical trials, NOVOBLISS has developed each component of the clinical trial services, starting with pre-sales business development, legal, finance, scientific marketing, scientific writers, including Ph.D. scholars, clinical trials patients’ database, database of investigators and KOLs, and database on clinical trial sites, hospitals, and laboratories.

NOVOBLISS Research provides clinical trial support for some of the major FMCG products that are used on a daily basis with the goal of providing high-quality, scientifically supported data
Maheshvari Patel //Founder

NOVOBLISS focus is on the FMCG sector where skin, hair, and personal hygiene are of the utmost importance. Testing topical cosmetics and pharmaceutical products with high standards and globally accepted trial designs, specialized knowledge of highly experienced workers, and identity as one of the few high-quality CROs in the cosmetic industry, are just a few of the ways NOVOBLISS stands out from the competition.

Future Roadmap
The path of NOVOBLISS has been a roller-coaster, starting with just two team members at the inception of the company and growing to a strength of 20 full-time employees and 20 part-time contractual staff. The firm has completed more than 60 clinical trials on consumer goods, including oral care, eye care, cosmetics, food, nutraceuticals, skin care, hair care, and baby care. Moving forward, NOVOBLISS wants to launch subsidiary company activities in the US, EU region and Canada by December 2023. NOVOBLISS is expanding rapidly and is now looking to expand internationally as it anticipates forming a joint venture with well-known brands.